LatticePoint is a boutique consulting firm working with various biopharma companies and investors to help define, establish and defend the value of their products in key markets around the world. LatticePoint is led by former industry market access leaders who understand how to plan for the political, scientific and financial realities that will be pivotal in negotiating product access. The output of our work product is used for product commercialization, valuations for investment decisions, licensing and M&A due diligence. Our clients consist of investors, start-ups, commercial-stage, and post-LOE companies across a variety of therapeutic areas, for orphan and non-orphan indications, in oncology, genetic diseases, including cell and gene therapies, and many others.
LatticePoint has offices in Switzerland and the United States.